NOVO ANÁLOGO DE INSULINA E SUA UTILIZAÇÃO
Patent Information
- Application Number
- BR112015019985
- Authority / Receiving Office
- BR · BR
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2014-01-20
- Filing Date
- 2014-02-26
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2034-02-26
AI Technical Summary
Existing insulin formulations have a short in vivo half-life, requiring frequent administration, which causes discomfort for diabetic patients, and existing insulin analogs with reduced receptor binding affinity fail to significantly extend the half-life due to renal clearance.
Development of an insulin analogue with a non-native sequence and reduced insulin receptor binding affinity, conjugated with the Fc fragment of immunoglobulin via a non-peptidic polymer linker to increase the half-life.
The insulin analogue conjugate achieves a significantly prolonged half-life in the blood, reducing the frequency of administration and improving patient convenience.
Abstract
Description
[002] The present invention relates to an insulin analogue having a reduced insulin titer and a reduced insulin receptor binding affinity compared with the native form for the purpose of increasing the half-life of insulin in the blood, to a conjugate prepared by linking the insulin analogue and a carrier, to a long-acting formulation comprising the conjugate and to a method for preparing the conjugate.
[003] [Previous technique]
[004] It is known that proteins in vivo are eliminated through various pathways, such as degradation by proteolytic enzymes in the blood, excretion through the kidneys, or clearance by receptors. Thus, efforts have been made to improve therapeutic efficacy by avoiding protein clearance mechanisms and increasing the half-life of physiologically active proteins.
[005] On the other hand, insulin is a hormone secreted by the pancreas in the human body that regulates blood glucose levels and plays a role in maintaining normal blood glucose levels by transporting excess glucose from the blood to cells to provide energy to the cells. However, in diabetic patients, insulin does not function correctly due to a lack of insulin, insulin resistance, and loss of beta cell function, so blood glucose cannot be used as an energy source and blood glucose levels are elevated, leading to hyperglycemia. Finally, urinary excretion occurs, which contributes to the development of various complications. Therefore, insulin therapy is essential for patients with abnormal insulin secretion (type I) or insulin resistance (type II), and blood glucose levels can usually be regulated through insulin administration. However, such 2 / 40 Like other protein and peptide hormones, insulin has a very short in vivo half-life and thus has the disadvantage of requiring repeated administration. Such frequent administration causes severe pain and discomfort for patients. For this reason, to improve quality of life by increasing the in vivo half-life of the protein and reducing the frequency of administration, several studies have been conducted on protein formulation and chemical conjugation (conjugated with fatty acid, conjugated with polyethylene polymers). Commercially available long-acting insulin includes insulin-glargine marketed by Sanofi Aventis (Lantus, with a duration of approximately 20 to 22 hours) and insulin-detemir (Levemir, with a duration of approximately 18 to 22 hours) and Tresiba (Degludec, with a duration of approximately 40 hours) marketed by Novo Nordisk.These long-acting formulations do not produce a peak in blood insulin concentration, thus being suitable as basal insulin. However, since these formulations do not have a sufficiently long half-life, the disadvantages of one or two injections per day still remain. Therefore, there are limitations in achieving the intended goal of markedly reducing the frequency of administration in order to improve convenience for diabetic patients who require long-term administration.
[006] Previous research has reported a specific in vivo insulin clearance process; 50% or more of insulin is removed in the kidneys, with the remaining portion removed via a receptor-mediated elimination process (RMC) at target sites such as muscles, fat, liver, etc.
[007] In this sense, many studies, including J Pharmacol Exp Ther (1998) 286: 959, Diabetes Care (1990) 13: 923, Diabetes (1990) 39:1033, have described that in vitro activity is reduced to avoid insulin CMR, thus increasing blood levels. However, these insulin analogs that have reduced receptor binding affinity cannot avoid renal clearance, which constitutes a major elimination mechanism, although CMR is 3 / 40 reduced. Therefore, a limit was observed in considerably increasing the half-life in the blood.
[008] Based on this background, the applicants have conducted numerous experiments with the aim of increasing the half-life of insulin in the blood. As a result, they have found that a novel insulin analogue, which does not have any native insulin sequence but rather a non-native insulin sequence, exhibits a reduced in vitro titer and a reduced insulin receptor binding affinity, and therefore, its renal clearance is reduced. They have further found that the half-life of insulin can be further increased by binding the insulin analogue to an Fc fragment of immunoglobulin, as an effective representative vehicle for improving the half-life, thus completing the present invention.
[009] [Description]
[010] [Technical problems]
[011] It is an object of the present invention to provide an insulin analogue that is prepared in such a way as to have a reduced titer in vitro with the aim of prolonging the half-life of insulin in vivo and a conjugate prepared by linking a vehicle to it.
[012] Specifically, it is an object of the present invention to provide an insulin analogue that has a reduced insulin titer compared to the native form.
[013] Another object of the present invention is to provide an insulin analogue conjugate that is prepared by linking the insulin analogue to the vehicle.
[014] It is yet another object of the present invention to provide a long-acting insulin formulation that includes the insulin analogue conjugate.
[015] It is yet another object of the present invention to provide a method for preparing the insulin analogue conjugate.
[016] It is yet another object of the present invention to provide a 4 / 40 method for increasing the in vivo half-life of the insulin analogue or insulin analogue conjugate prepared by linking the insulin analogue to the vehicle.
[017] It is yet another object of the present invention to provide a method for treating insulin-related diseases, including the step of administering an insulin analogue or insulin analogue conjugate to a subject who needs it.
[018] [Technical solution]
[019] In accordance with one aspect of achieving the foregoing objects, the present invention provides an insulin analogue with a reduced insulin titer, compared with the native amino acid form, in which an amino acid of the B chain or the A chain is modified.
[020] According to a specific variant, the present invention provides an insulin analogue with reduced insulin receptor binding affinity.
[021] According to another specific variant, the present invention provides a non-native insulin analogue, in which an amino acid selected from the set consisting of 8Qamino acid, 23Qamino acid, 24Qamino acid and 25Qamino acid of chain B and 1Qamino acid, 2Qamino acid and 19Qamino acid of chain A is substituted with alanine or in which 14Qamino acid of chain A is substituted with glutamic acid or asparagine in the insulin analogue according to the present invention.
[022] According to yet another specific variant, the present invention provides an insulin analogue, wherein the insulin analogue according to the present invention is selected from the set consisting of SEQ ID Nos. 20, 22, 24, 26, 28, 30, 32, 34 and 36.
[023] According to another aspect, the present invention provides an insulin analogue conjugate that is prepared by linking the insulin analogue described above to a vehicle capable of prolonging the half-life.
[024] According to a specific variant, the present invention 5 / 40 provides an insulin analog conjugate, wherein the insulin analog conjugate is prepared by linking (i) the insulin analog described above and (ii) an Fc region of immunoglobulin via a peptide linker selected from the set consisting of polyethylene glycol, polypropylene glycol, ethylene glycol-propylene glycol copolymers, polyoxyethylated polyols, polyvinyl alcohols, polysaccharides, dextran, polyvinyl ethyl ether, biodegradable polymers, lipid polymers, chitins, hyaluronic acid and a combination thereof.
[025] In yet another aspect, the present invention provides a long-acting insulin formulation that includes the insulin analogue conjugate described above, in which the duration and stability in vivo are increased.
[026] According to a specific variant, the present invention provides a long-acting formulation that is used for the treatment of diabetes.
[027] According to another variant, the present invention provides a method for preparing the insulin analogue conjugate described above.
[028] According to yet another specific variant, the present invention provides a method for increasing the in vivo half-life using the insulin analog or the insulin analog conjugate that is prepared by linking the insulin analog and the vehicle.
[029] According to yet another specific variant, the present invention provides a method for treating insulin-related diseases, including the step of administering an insulin analogue or an insulin analogue conjugate to a subject who needs it.
[030] [Advantageous effects]
[031] A non-native insulin analogue of the present invention has a reduced insulin titer and a reduced insulin receptor binding affinity compared to the native form, thus avoiding in vivo elimination mechanisms. Therefore, the insulin analogue has a semi-native half-life. 6 / 40 has an increased in vivo half-life in blood, and an immunoglobulin-Fc insulin analog conjugate prepared using the same exhibits a significantly increased half-life in blood, thus improving the convenience for patients requiring insulin administration.
[032] [Description of the figures]
[033] FIG. 1 shows the result of the purity analysis of an insulin analogue by protein electrophoresis, which represents the result of the representative insulin analogue, analogue nQ. 7 (Line 1: size marker, Line 2: native insulin, Line 3: insulin analogue (nQ. 7);
[034] FIG. 2 shows the result of the purity analysis of an insulin analogue by high-throughput chromatography, which represents the result of the representative insulin analogue, analogue nQ. 7 ((A) RP-HPLC, (B) SEHPLC);
[035] FIG. 3 shows the result of peptide mapping of an insulin analogue, which represents the result of the representative insulin analogue, analogue nQ. 7 ((A) native insulin, (B) insulin analogue (nQ. 7));
[036] FIG. 4 shows the result of purity analysis of an insulin analogue-Fc immunoglobulin conjugate by protein electrophoresis, which represents the result of the representative insulin analogue, analogue nQ. 7 (Line 1: size marker, Line 2: insulin analogue (nQ. 7)-Fc immunoglobulin conjugate);
[037] FIG. 5 shows the result of the purity analysis of an insulin-Fc immunoglobulin analogue conjugate by high-throughput chromatography, which represents the result of the representative insulin analogue, analogue nQ. 7 ((A) RP-HPLC, (B) SE-HPLC, (C) IE-HPLC) and
[038] FIG. 6 shows the result of the pharmacokinetic analysis of the native insulin-Fc immunoglobulin conjugate and the insulin-Fc immunoglobulin analog conjugate in normal rats, which represents the result of the representative insulin analog, nQ analog. 7 (o: native insulin-Fc immunoglobulin conjugate (21.7 nmol / kg), ·: native insulin-Fc conjugate 7 / 40 immunoglobulin (65.1 nmol / kg), □: insulin analog-Fc immunoglobulin conjugate (21.7 nmol / kg), : insulin analog-Fc immunoglobulin conjugate (65.1 nmol / kg). (A) native insulin-Fc immunoglobulin conjugate and insulin analog conjugate (nQ.7 analog)-Fc immunoglobulin, (B) native insulin-Fc immunoglobulin conjugate and insulin analog conjugate (nQ.8 analog)-Fc immunoglobulin, (C) native insulin-Fc immunoglobulin conjugate and insulin analog conjugate (nQ.9 analog)-Fc immunoglobulin).
[039] [Best embodiment of the invention]
[040] The present invention relates to an insulin-derived analogue with a reduced in vitro insulin titer. This insulin analogue is characterized by having a non-native insulin sequence and thus having a reduced insulin receptor binding affinity compared to the native form, and consequently significantly reduced receptor-mediated elimination through an increase in the dissociation constant, resulting in an increased half-life in the blood.
[041] As used herein, the term “insulin analogue” includes various analogues with a reduced insulin titer compared to the native form.
[042] An insulin analogue may be an insulin analogue with a reduced insulin titer, compared to the native form, in which an amino acid of the B chain or the A chain of insulin is modified. The amino acid sequences of native insulin are as follows.
[043] - Chain A:
[044] Gly-lle-Val-Glu-GIn-Cys-Cys-Thr-Ser-lle-Cys-Ser-Leu-Tyr-GIn-LeuGlu-Asn-Tyr-Cys-Asn (SEQ ID NO. 37)
[045] - Chain B:
[046] Phe-Val-Asn-Gln-His-Leu-Cys-Gly-Ser-His-Leu-Val-Glu-Ala-Leu-TyrLeu-Val-Cys-Gly-Glu-Arg-Gly-Phe-Phe-Tyr-Thr-Pro-Lys-Thr (SEQ ID NO. 38).
[047] The insulin analogue used in the examples of the present invention is 8 / 40 an insulin analogue prepared by means of a genetic recombination technique. However, the present invention is not limited to this, including all insulins that have a reduced titer in vitro. Preferably, the insulin analogue may include inverted insulins, insulin variants, insulin fragments or the like, and the preparation method may include a solid-phase method as well as a genetic recombination technique, but is not limited to these.
[048] An insulin analogue is a peptide that maintains a blood glucose control function in the body, which is identical to that of insulin, and this peptide comprises agonists, derivatives and fragments of insulin, its variants or similar forms.
[049] The insulin agonist of the present invention relates to a substance that is bound to the insulin receptor in vivo to exhibit the same biological activities as insulin, regardless of the structure of insulin.
[050] The insulin analog of the present invention designates a peptide that exhibits at least 80% sequence homology in an amino acid sequence when compared with the A chain or the B chain of native insulin, has some groups of amino acid residues altered in the form of chemical substitution (e.g., alpha-methylation, alpha-hydroxylation), removal (e.g., deamination) or modification (e.g., N-methylation), and has a function of controlling blood glucose levels in the body. With respect to the objects of the present invention, the insulin analog is an insulin analog that has a reduced insulin receptor binding affinity compared to the native form, and includes, without limitation, insulin analogs that have a reduced insulin titer compared to native insulin.
[051] As long as the insulin analog is capable of exhibiting reduced receptor-mediated internalization or receptor-mediated elimination, its type and size are not particularly limited. An insulin analog whose main in vivo elimination mechanism is receptor-mediated internalization or receptor-mediated elimination is suitable for 9 / 40 the objects of the present invention.
[052] The insulin fragment designates the type of insulin in which one or more amino acids are added or removed, where the added amino acids may be non-native amino acids (e.g., D-type amino acids). Such insulin fragments maintain the function of controlling blood glucose in the body.
[053] The insulin variant of the present invention designates a peptide that differs from insulin in one or more amino acid sequences and that maintains the function of controlling blood glucose in the body.
[054] The respective methods for preparing insulin agonists, derivatives, fragments and variants of the present invention may be used independently or in combination. For example, peptides in which one or more amino acid sequences differ from those of insulin and which exhibit deamination at the amino acid residue of the amine terminal and which also have the function of controlling blood glucose in the body are included in the present invention.
[055] Specifically, the insulin analog may be an insulin analog in which one or more amino acids selected from the set consisting of 8Qamino acid, 23Qamino acid, 24Qamino acid and 25Qamino acid of chain B and 1Qamino acid, 2Qamino acid, 14Qamino acid and 19Qamino acid of chain A are replaced with another amino acid and, preferably, where one or more amino acids selected from the set consisting of 8Qamino acid, 23Qamino acid, 24Qamino acid and 25Qamino acid of chain B and 1Qamino acid, 2Qamino acid and 19Qamino acid of chain A are replaced with alanine or wherein the 14Qamino acid of chain A is replaced with glutamic acid or asparagine. In addition, the insulin analog may be selected from the set consisting of SEQ ID NOs. 20, 22, 24, 26, 28, 30, 32, 34 and 36, but may include, without limitation, any insulin analogue that has reduced insulin receptor binding affinity. 10 / 40
[056] According to a variant of the present invention, it was concluded that the insulin analogs of SEQ ID NOs. 20, 22, 24, 26, 28, 30, 32, 34 and 36, in particular, the representative insulin analogs 7, 8 and 9 (SEQ ID NOs. 32, 34 and 36) have reduced insulin receptor binding affinity in vitro, compared to the native form (table 4).
[057] According to another aspect, the present invention provides an insulin analogue conjugate that is prepared by linking the insulin analogue and a carrier.
[058] As used herein, the term “vehicle” designates a substance capable of increasing the in vivo half-life of the linked insulin analog. The insulin analog according to the present invention is characterized by having a significantly reduced binding affinity to the insulin receptor, compared to the native form, and avoiding receptor-mediated elimination or renal elimination. Thus, when a vehicle, which is known to increase the in vivo half-life when linked to various known physiologically active polypeptides, is linked to the insulin analog, it is apparent that the in vivo half-life can be improved and that the resulting conjugate can be used as a long-acting formulation.
[059] For example, since improving half-life is the first priority, the vehicle intended to bind to the new insulin, which has a reduced titer, is not limited to the Fc region of immunoglobulin. The vehicle includes a biocompatible material capable of prolonging the half-life in vivo through its binding to any of the biocompatible materials capable of reducing renal elimination, selected from the set consisting of various polymers (e.g., polyethylene glycol and fatty acids, albumin and its fragments, particular amino acid sequences, etc.), albumin and its fragments, albumin-binding materials and polymers of repeating units of particular amino acid sequences, antibodies, antibody fragments, FcRn-binding materials, 11 / 40 connective tissue in vivo or its derivatives, nucleotides, fibronectin, transferrin, saccharides and polymers, although not limited to these. Furthermore, the method for binding biocompatible material capable of prolonging the in vivo half-life of the insulin analog with a reduced titer includes genetic recombination, in vitro conjugation or similar. Examples of biocompatible material include FcRn binding material, fatty acids, polyethylene glycol, an amino acid fragment or albumin. The FcRn binding material may be an Fc region of immunoglobulin.
[060] The insulin analogue and the biocompatible material, as a carrier, can be linked together by means of a peptide or a non-peptidic polymer, as a linker.
[061] The insulin conjugate may be an insulin analogue conjugate prepared by linking (i) the insulin analogue and (ii) the Fc region of immunoglobulin via (iii) a peptide linker or a non-peptide linker selected from the set consisting of polyethylene glycol, polypropylene glycol, ethylene glycol-propylene glycol copolymers, polyoxyethylated polyol, polyvinyl alcohol, polysaccharides, dextran, polyvinyl ethyl ether, biodegradable polymers, lipid polymers, chitins, hyaluronic acid and a combination thereof.
[062] According to a specific variant of the insulin analog conjugate of the present invention, a non-peptidic polymer is linked to the amino terminus of the B chain of the insulin analog. According to another specific variant of the conjugate of the present invention, a non-peptidic polymer is linked to the residue of the B chain of the insulin analog. The modification in the A chain of insulin results in a reduction in activity and safety. Therefore, according to these variants, the non-peptidic polymer, as a linker, is linked to the B chain of insulin, thus maintaining the activity of insulin and improving safety.
[063] As used herein, the term “activity” designates the ability of insulin to bind to the insulin receptor and indicates that insulin binds to 12 / 40 its receptor to exhibit its action. Such binding of the non-peptidic polymer to the amino terminus of the B chain of insulin of the present invention can be achieved by pH control, the preferred pH range being between 4.5 and 7.5.
[064] As used here, the term “N-terminal” can be used interchangeably with “N-terminal region”.
[065] According to a specific example, the applicants prepared an insulin-Fc immunoglobulin analog conjugate by PEG binding to the N-terminus of an Fc region of immunoglobulin and selectively coupling the N-terminus of the insulin chain to it. The serum half-life of this insulin-Fc immunoglobulin analog conjugate was increased compared to the unconjugated form, and it exhibited a hypoglycemic effect in animal models of the disease. Thus, it is apparent that it is possible to prepare a novel long-acting insulin formulation that maintains activity in vivo.
[066] The Fc region of immunoglobulin is safe for use as a drug carrier because it is a biodegradable polypeptide that is metabolized in vivo. Furthermore, the Fc region of immunoglobulin has a relatively low molecular weight compared to complete immunoglobulin molecules, thus being advantageous in terms of preparation, purification, and conjugate yield. The Fc region of immunoglobulin does not contain a Fab fragment, which is quite non-homogeneous due to the different amino acid sequences according to antibody subclasses, and thus it is possible to expect that the Fc region of immunoglobulin can significantly increase the homogeneity of substances and be less antigenic in the blood.
[067] As used herein, the term “immunoglobulin Fc region” designates a protein containing the constant 2 region of the heavy chain (CH2) and the constant 3 region of the heavy chain (CH3) of an immunoglobulin, excluding the variable regions of the heavy and light chains, the constant 1 region of the heavy chain (CH1) and the constant 1 region of the light chain (CL1) of the 13 / 40 immunoglobulin. It may also include a hinge region in the constant region of the heavy chain. Furthermore, the Fc region of immunoglobulin of the present invention may contain part or all of the Fc region, including the constant region 1 of the heavy chain (CH1) and / or the constant region 1 of the light chain (CL1), except for the variable regions of the heavy and light chains of immunoglobulin, provided that it exhibits an effect that is practically the same as or better than the effect of the native form. In addition, it may be a fragment that has a deletion in a relatively long portion of the amino acid sequence of CH2 and / or CH3.
[068] That is, the Fc region of immunoglobulin of the present invention may include 1) a CH1 domain, a CH2 domain, a CH3 domain and a CH4 domain, 2) a CH1 domain and a CH2 domain, 3) a CH1 domain and a CH3 domain, 4) a CH2 domain and a CH3 domain, 5) a combination of one or more domains and a hinge region (or a portion of a hinge region) and 6) a dimer of each domain of the constant regions of the heavy chain and the constant region of the light chain.
[069] Furthermore, the immunoglobulin Fc region of the present invention includes a derived (mutant) sequence as well as a native amino acid sequence. A derived amino acid sequence has a sequence that differs from the native amino acid sequence due to a deletion, insertion, non-conservative or conservative substitution, or combinations thereof, of one or more amino acid residues. For example, in an IgG Fc region, the amino acid residues known to be important for binding, at positions 214 to 238, 297 to 299, 318 to 322, or 327 to 331, can be used as a suitable target for modification.
[070] Furthermore, other derivatives are possible, including derivatives that exhibit a deletion of a region capable of forming a disulfide bridge, a deletion of several amino acid residues at the N-terminus of a native Fc form, or an addition of a methionine residue at the N-terminus of a native Fc form. In addition, to remove effector functions, it can 14 / 40 There may be a deletion at a complement binding site, such as a C1q binding site and an ADCC (antibody-dependent cell-mediated cytotoxicity) site. Techniques for preparing such sequences derived from the Fc region of immunoglobulin are described in documents WO 97 / 34631 and WO 96 / 32478.
[071] Amino acid exchanges in proteins and peptides, which do not normally alter the activity of the molecules, are known in the field (H.Neurath, RLHill, The Proteins, Academic Press, New York, 1979). The exchanges that occur most commonly are Ala / Ser, Val / lle, Asp / Glu, Thr / Ser, Ala / Gly, Ala / Thr, Ser / Asn, Ala / Val, Ser / Gly, Thy / Phe, Ala / Pro, Lys / Arg, Asp / Asn, Leu / lle, Leu / Val, Ala / Glu, Asp / Gly, in both directions.
[072] If desired, the Fc region can be modified by phosphorylation, sulfonation, acrylation, glycosylation, methylation, farnesylation, acetylation, amidation or similar.
[073] The aforementioned Fc derivatives are derivatives that exhibit biological activity identical to that of the Fc region of the present invention or improved structural stability against heat, pH or the like.
[074] Furthermore, these Fc regions can be obtained from native forms isolated from humans and other animals, including cows, goats, pigs, mice, rabbits, hamsters, rats, and guinea pigs, or they can be recombinant or derivatives obtained from animal cells or transformed microorganisms. In this case, they can be obtained from a native immunoglobulin by isolating complete immunoglobulins from humans or animal organisms and treating them with a proteolytic enzyme. Papain digests the native immunoglobulin to obtain the Fab and Fc regions, and treatment with pepsin provides the production of pF'c and F(ab)2. These fragments can be subjected to size exclusion chromatography to isolate Fc or pF'c.
[075] Preferably, an Fc region originating from humans is a region 15 / 40 Recombinant Fc immunoglobulin that is obtained from a microorganism.
[076] Furthermore, the Fc region of immunoglobulin may be in a form that has native sugar chains, an increase in sugar chains compared to the native form, or a decrease in sugar chains compared to the native form, or it may be in a deglycosylated form. Increasing, decreasing, or removing Fc immunoglobulin sugar chains can be achieved by methods common in the specialty, such as a chemical method, an enzymatic method, and a genetic engineering method using a microorganism. In this case, removing sugar chains from an Fc region results in a marked decrease in complement binding affinity (c1q) and a decrease or loss in antibody-dependent cell-mediated cytotoxicity or complement-dependent cytotoxicity, thus not inducing unnecessary immune responses in vivo.In this regard, an Fc region of immunoglobulin in a deglycosylated or aglycosylated form may be more suitable for the object of the present invention as a drug carrier.
[077] The term “deglycosylation”, as used herein, designates the enzymatic removal of sugar residues from the Fc region and the term “aglycosylation” designates that an Fc region is produced in a non-glycosylated form by a prokaryote, preferably E. coii.
[078] On the other hand, the Fc region of immunoglobulin can be obtained from humans or other animals, including cows, goats, pigs, mice, rabbits, hamsters, rats and guinea pigs, and preferably humans. Furthermore, the Fc region of immunoglobulin can be an Fc region that is derived from IgG, IgA, IgD, IgE and IgM or it can be made from combinations or hybrids thereof. Preferably, it is derived from IgG or IgM, which are among the most abundant proteins in human blood, and more preferably from IgG, which is known to increase the half-lives of ligand-binding proteins.
[079] On the other hand, the term “combination”, as used here, designates 16 / 40 that polypeptides encoding single-chain immunoglobulin Fc regions of the same origin are linked to a single-chain polypeptide of a different origin to form a dimer or a multimer. That is, it is possible to form a dimer or multimer from two or more fragments selected from the set consisting of Fc fragments of IgG, IgA, IgM, IgD, and IgE.
[080] The term “hybrid,” as used herein, designates sequences encoding two or more immunoglobulin Fc regions of different origins that are present in a single-chain immunoglobulin Fc region. According to the present invention, several types of hybrids are possible. That is, hybrid domains may consist of one to four domains selected from the set consisting of CH1, CH2, CH3, and CH4 of IgG Fc, IgM Fc, IgA Fc, IgE Fc, and IgD Fc, and may include the hinge region.
[081] On the other hand, IgG is divided into the subclasses IgG1, IgG2, IgG3 and IgG4, and the present invention includes combinations and hybrids thereof. The IgG2 and IgG4 subclasses are preferred, and the Fc region of IgG4, which rarely has effector functions such as CDC (complement-dependent cytotoxicity), is more preferred. That is, as a drug carrier of the present invention, the most preferred immunoglobulin Fc region is a non-glycosylated Fc region obtained from human IgG4. The Fc region from humans is more preferred than an Fc region from non-humans, which can act as an antigen in the human body and can cause undesirable immune responses, such as the production of a new antibody against the antigen.
[082] Depending on the specific variant of the insulin analogue conjugate, both ends of the non-peptidic polymer can be linked to the N-terminus of the Fc region of immunoglobulin and to the amine group of the N-terminus of the B chain of the insulin receptor or to the ε-amino group or to the thiol group of the internal lysine residue of the B chain, respectively.
[083] The insulin-linker-Fc region analogue of the present invention is made 17 / 40 in various molar ratios. That is, the number of Fc fragments and / or linkers attached to an individual insulin analog is not limited.
[084] Furthermore, the linkage of the Fc region, a given linker, and the insulin analog of the present invention may include all types of covalent and non-covalent linkages, such as hydrogen bonds, ionic interactions, van der Waals forces, and hydrophobic interactions, when the Fc region and the insulin analog are expressed as a genetic recombination fusion protein. However, with regard to the physiological activity of the insulin analog, the linkage is preferably effected by covalent bonds, although it is not limited to these.
[085] On the other hand, the Fc region of the present invention, a given linker and the insulin analogue may be linked together at an N-terminus or C-terminus and, preferably, at a free group, and, in particular, a covalent bond may be formed at an amino-terminal end, at a lysine amino acid residue, at a histidine amino acid residue or at a free cysteine residue.
[086] Furthermore, the linking of the Fc region of the present invention, a given linker and the insulin analog can be effected in a given direction. That is, the linker can be linked to the N-terminus, the C-terminus or a free group of the Fc region of immunoglobulin and can also be linked to the N-terminus, the C-terminus or a free group of the insulin analog.
[087] The non-peptidic linker can be linked to the N-terminal amine group of the immunoglobulin fragment and is not limited to any of the lysine or cysteine residues of the immunoglobulin fragment sequence.
[088] Furthermore, according to the specific variant of the insulin analogue conjugate, the non-peptidic polymer end may be linked to the internal amino acid residue or free reactive group capable of binding to the reactive group at the non-peptidic polymer end, in addition to the N-terminus of the immunoglobulin Fc region, although it is not limited to this.
[089] In the present invention, the non-peptidic polymer designates a polymer 18 / 40 biocompatible polymer comprising two or more repeating units linked together, wherein the repeating units are linked by any covalent bond excluding peptide bonds. Such a non-peptidic polymer may have two ends or three ends.
[090] The non-peptidic polymer that can be used in the present invention can be selected from the set consisting of polyethylene glycol, polypropylene glycol, ethylene glycol and propylene glycol copolymers, polyoxyethylated polyols, polyvinyl alcohol, polysaccharides, dextran, polyvinyl ethyl ether, biodegradable polymers such as PLA (poly(lactic) acid) and PLGA (polylactic-glycolic acid), lipid polymers, chitins, hyaluronic acid and their combinations and, preferably, polyethylene glycol. Well-known derivatives of these, easily prepared by those skilled in the art, are also included within the scope of the present invention.
[091] The peptide linker used in the fusion protein obtained through a conventional framed fusion method has disadvantages because it is easily cleaved in vivo by a proteolytic enzyme and, therefore, it is not possible to obtain a sufficient increase in the blood half-life of the active drug by a vehicle, as expected. However, in the present invention, the conjugate can be prepared using the non-peptide linker as well as the peptide linker. In the case of the non-peptide linker, the polymer with resistance to the proteolytic enzyme can be used to maintain the blood half-life of the peptide similar to that of the vehicle. Thus, it is possible to use without limitation any non-peptide polymer, provided that it is a polymer that possesses the aforementioned function, that is, a polymer with resistance to the proteolytic enzyme in vivo.The non-peptidic polymer has a molecular weight between 1 and 100 kDa, and preferably between 1 and 20 kDa.
[092] The non-peptyl polymer of the present invention, linked to the Fc region of immunoglobulin, may be a polymer or a combination of different types of polymers. 19 / 40
[093] The non-peptidic polymer used in the present invention has a reactive group capable of binding to the Fc region of immunoglobulin and to the protein drug.
[094] The non-peptidic polymer has a reactive group at both ends, which is preferably selected from the set consisting of a reactive aldehyde group, a propionaldehyde group, a butyraldehyde group, a maleimide group, and a succinimide derivative. The succinimide derivative may be succinimidyl propionate, hydroxy-succinimidyl, carboxymethyl-succinimidyl, or succinimidyl carbonate. In particular, when the non-peptidic polymer has a reactive aldehyde group at both ends, it is effective for linking both ends to a physiologically active polypeptide and an immunoglobulin with minimal non-specific reactions. An end product generated by reductive alkylation via an aldehyde linkage is much more stable than one linked via an amide linkage.The reactive aldehyde group selectively binds to an N-terminus at a low pH value and binds to a lysine residue to form a covalent bond at a high pH, such as pH 9.0.
[095] The reactive groups at both ends of the non-peptidic polymer may be the same or different from each other. For example, the non-peptidic polymer may have a maleimide group at one end and an aldehyde group, a propionaldehyde group, or a butyraldehyde group at the other end. When using a polyethylene glycol with a reactive hydroxyl group at both ends as the non-peptidic polymer, then the hydroxyl group can be activated to various reactive groups by means of known chemical reactions, or it is possible to use a commercially available modified polyethylene glycol with a modified reactive group to prepare the single-chain insulin analog conjugate of the present invention.
[096] The insulin analogue conjugate of the present invention maintains the in vivo activity of conventional insulin, such as energy metabolism and sugar metabolism, and further increases the blood half-life of The 20 / 40 insulin analog significantly increases the duration of the peptide's in-vivo efficacy, making the conjugate useful in the treatment of diabetes.
[097] In an example of the present invention, it was confirmed that the insulin analogue with a reduced insulin receptor binding affinity exhibits a much longer in vivo half-life than the native insulin conjugate when bound to the vehicle capable of prolonging the in vivo half-life (FIG. 6).
[098] According to another aspect, the present invention provides a long-acting insulin formulation that includes the insulin analogue conjugate.
[099] A long-acting insulin formulation may be a long-acting insulin formulation with increased duration and stability in vivo. The long-acting formulation may be a pharmaceutical composition for the treatment of diabetes.
[100] The pharmaceutical composition comprising the conjugate of the present invention may comprise pharmaceutically acceptable vehicles. For oral administration, the pharmaceutically acceptable vehicle may comprise a binder, a lubricant, a disintegrating agent, an excipient, a dissolving agent, a dispersing agent, a stabilizer, a suspending agent, a colorant, a perfume, or the like. For injectable preparations, the pharmaceutically acceptable vehicle may comprise a buffering agent, a preservative, an analgesic, a dissolving agent, an isotonic agent, and a stabilizer. For topical preparations, the pharmaceutically acceptable vehicle may comprise a base, an excipient, a lubricant, a preservative, or the like. The pharmaceutical composition of the present invention may be formulated in a variety of dosage forms in combination with the pharmaceutically acceptable vehicles referred to above.For example, for oral administration, the pharmaceutical composition may be formulated as tablets, triglycerides, capsules, elixirs, suspensions, syrups, or lozenges. 21 / 40 For injectable preparations, the pharmaceutical composition may be formulated in single-dose ampoules or in multi-dose containers. The pharmaceutical composition may also be formulated as solutions, suspensions, tablets, pills, capsules, and delayed-release preparations.
[101] On the other hand, examples of suitable vehicles, excipients and diluents for formulation include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum derivative, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oils or the like.
[102] Furthermore, pharmaceutical formulations may also include fillers, anticoagulants, lubricants, humectants, perfumes, antiseptics or similar substances.
[103] According to another aspect, the present invention provides a method for treating insulin-related diseases, which includes administering the insulin analogue conjugate to a subject who needs it.
[104] The conjugate according to the present invention is useful for the treatment of diabetes and thus this disease can be treated by administering the pharmaceutical composition comprising the same.
[105] The term “administration,” as used herein, designates the introduction of a predetermined substance into a patient by means of a specific suitable method. The conjugate of the present invention can be administered by any of the common routes, provided it is capable of reaching the desired tissue. Administration is possible via intraperitoneal, intravenous, intramuscular, subcutaneous, intradermal, oral, topical, intranasal, intrapulmonary, and intrarectal routes, although the present invention is not limited to these. However, since peptides are deferred after oral administration, the active ingredients of a composition for oral administration should be coated or formulated for protection. 22 / 40 against degradation in the stomach. Preferably, the present composition can be administered in an injectable form. Furthermore, the pharmaceutical composition can be administered using a specific device capable of transporting the active ingredients to a target cell.
[106] Furthermore, the pharmaceutical composition of the present invention can be determined by several associated factors, including the type of disease to be treated, the routes of administration, the age, gender and weight of the patient and the severity of the disease, as well as the types of drugs used as the active component. Since the pharmaceutical composition of the present invention has an excellent duration and in vivo titer, it has the advantage of significantly reducing the frequency of administration of the pharmaceutical formulation of the present invention.
[107] In yet another aspect, the present invention provides a method for preparing the insulin analogue conjugate, including the preparation of the insulin analogue; the preparation of the vehicle and the linking of the insulin analogue and the vehicle.
[108] In yet another aspect, the present invention provides a method for increasing the in vivo half-life using the insulin analogue or insulin analogue conjugate, which is prepared by linking the insulin analogue and the vehicle.
[109] [Method for the invention]
[110] Hereafter, the present invention will be described in more detail by reference to examples. However, these examples are for illustrative purposes only, and the invention is not intended to be limited by these examples.
[111] Example 1: preparation of the single-chain insulin analog expression vector
[112] To prepare insulin analogs, each having a modified amino acid in the A or B chain, using the native insulin expression vector as a template, direct oligonucleotides were synthesized. 23 / 40 and reverses (Table 2) and then subjected to PCR to amplify each analog gene.
[113] In the following table 1, the modified amino acid sequences in chain A and chain B are presented, as well as the names of the analogues. That is, analogue 1 represents that 1α-glycine of chain A is replaced with alanine and analogue 4 represents that 8α-glycine of chain B is replaced with alanine.
[114] [Quadrol] Analog Modified Sequence Analog 1 A^GA Analog 2 Analog 3 AIW —* A ' < 5· ' < < Analog 4 8^ — A Analog 5 Analog 6 RAF A Analog 7 Analog 8 A1* 7 — E Analog 9 H
[115] The primers for insulin analogue amplification are presented in Table 2 below. 24 / 40 [Table 2]
[116] PCR for amplification of the insulin analog was performed under 95QC conditions for 30 seconds, 55QC for 30 seconds, and 68QC for 6 minutes, for 18 cycles. The insulin analog fragments obtained under these conditions were inserted into the pET22b vector to be expressed as intracellular inclusion bodies, and the resulting expression vectors were named pET22b-insulin analogs 1 to 9. The expression vectors contain nucleic acids encoding the sequences of 25 / 40 amino acids of insulin analogs 1 to 10 under the control of the T7 promoter and the insulin analog proteins were expressed as inclusion bodies in host cells.
[117] The DNA sequences and protein sequences of insulin analogues 1 to 9 are presented in Table 3 below.
[118] [Table 3] 26 / 40 Analogous Λ\\νν·Λ·.·Λ·.>Λ'.·\'Λ·Λ>, AM;«yp 1 Sequence ío Dia sTC CsM AÀC. CAA MC CM W CMC KA CAC CM -GTé NOT CM | 19 WHAT CM S TA CMaKK CHMCMsAA Ç CM CMC ?K *M IAC ACACCíM AAÇ ACC HERE SÇM CMS WHAT IS CMC CSC? CAO CT& CACC C>M CsA(j CMC CMs CMC «T CXC «CA CMC ASX CT© CÀCm<XC Tt« (SCC C CC> (M(SCM> ?CC C Μ C AS AAG CM (K(s MS MCm CsAAC AA Mc ΚΠ AC C AcX AK TíK VA MC IAS SAS JCMs AAC ?AC 1ÓC AAC ; MsXsM. SM vS Aw (M cm MM· CMS? Sys· Ms Císs VX Çsss AX Ms Tys CssM M yy Cy$:«ç Sãs As« S y PM PM Ms sM As» (y\ Ms· Msj Μg sCss s Aá s Aá s SM Cysy CMCy W Ml « y AX «ki Xa Csx (Μ Μλ C6S.Í Ab Cm C4s (Cy 'W Sm c>R Sm AU M MS» SM (M Cy< 'Μ m C>. Ms m <s; (y? Ms Ms íM '' <'· Μ (Μ ( ASM v» sM AAC ?>AMW $M sXí MA CAC CM CAM SAA CM UC MA é*G Ci'sC COO UAA CM (MC MS TAC AC A CCS AM CAÍ CCM SACs MCA SsCS ç «m MCs CMC Mü ( AM S<A(s ( ϊ m (XS CCV (MC C CS (W CA A (MC A(M C1C* (Aé ('Cs CAC CTCs Cs Ms (ÁM ICC ‘MM CM> ΑΜ»<ΜΪ CAsC CW SM CAÁ MC SM ÃÇC Amc MC KM MC CK CAC <45 CM FwMW ΑΛζ 'AC ICC AAC Á $ $ > cM κα ΜΑ.? C c ><M M> Ha Μλ CSS CM sMs Sw 1 ys Cw j > CS M Aíy (Cy My M Mr M <> (ys Ms Mg (M ASs «M 1® CM SM CM CM CM CM MA; SM C<y SÇ Pm SM AM CM Λί CM Pm (.$« ΛΜ> (<>;$ Mís αγ Ms Ms «MM$ í>y· At» MM Cy;; Cv> SM Çs-ss· Çs' CyS Sáss 'sys CsX (yss .><< A-íss Cy>j AMM® 3 AD^ SH AA<. CM CA ΛΑ s 2< SM CIA UTM MS OAA MCA MCA ITS VC 'AC ASA CCS ACC MC>C CW MAC CAA «AS OM. í· ?U CAC C>lU ÍH» CAM MAM CCM < / > / . MMÁ CasC MCI M (XA <AA ACC (X SAO M TTC><s(X OGéAéCíCM MC <Χ&CAM AACCXTCM· ATTC<M SAACÁA (CsC AM MC AAC A1C sC> C MC C C. 1AC CAM C'ICs(CMC CAM CsC.Cs MsC ÀAc FSs^Sp^ VA As.í><M MA ;.> M0 to M MA Ms VsS CM Air Sm Cys X. of CM Ases Çsy Msm Px* Ms JM Sm Ma «λ Àsfj A>'g (M Asa A^m Cm ÇM SM CM \>5í Ml <>(« sM CM «y CM Cm CM ACs íZy à (M SM Ass (M <<?> 5^· 1«3 lys Aí^ sAy M Mas λ·;λ Cá Cys Ms sfe < am Am; Ty CS (µ Cm / í Am ΑΆ Ç^m 27 / 40 í AON ΗΊί UsS .MÇ CM ÇAt >A> Μ X:t· MA CAC Má. í CAAG Λί\χ f.oC CGG· GAG GCA G&G GAC € TG CAG Go? ?O CAts ÁO.> CG? GOO >M i GGo €A& TGTACX AGC AiX ?GC PCC OC CáG £&G CPGGAGí ÍÃA\ CAA ?XX ÂAx : i í FM W> Ás-ss Uss's Msí HA 1M. ?h í VA CM Xy 'Ms Aj^ -Xy FM FM sys Ms AH Α>Ή Uss Ash sys*s AU; 7 7 st X WH jMss sM Cys Uys Μ Μ- M ?y, Csss Ms MX>s 7b Asss it \M fAvs ;it A xAx t bo 0^0 mAA vt>: re w cca o?G w ggggmcgagcg n< gx w açacccI i:AAO ACC CCA Coo GAG CXA -GAA GAC CPS CAS SPo CSC CAGI CSto oAS C.?C PAX Soo CSC \Am Go? \$CA GoC AGx C?G GAGi OX-X v <G OxC CCG sas Ggo ?xx -so t Ao AAG Co? OGx- Α?ϊ οχ?· \>A^ CAA?Ox >O? Axx- Aot. ACt. Xi.$t x,$y 5 Ax t AG x?G xxAO: \ s > ΑΑχ s Ax Col A At $ ÍMMsM s Fm VX Asss Uiss Hs $ Lw V ys· súy Ms híj sMs sM CsSy Ms f. ,χ; s ys svy s svs? xys Us?S.sSss Assy FAhS'v-Sss X's <s'ss Css's v?? FFs Assy Assy Msi As-sy S<M Assis Ms M s Μ Ms VM Ms Ms M' hs? Ms sysy AU (siy; sMs Ms Uss's Fsss CAss AU SMs Ms Uss Ms Mss CM sy< Asy^ Uy· M VAC Mss sMs Cyy Cm ass Ms M Cy< M s W Sys Ms Ms Ms A%ss Tys CyM •W ? i í AON hsC Ms AÁÇ CAA CÁÇ UM MT MX st A VAC t TU MU MA Miss SMC My C U>M Ms; MUCsAA. CMMst MX TTC Mt As (A CM ΐ : AAs, s<> < cxA. ts.y.s CSÁU Sst.A SSsACs SSsAs. S. S sS CAH UUs UCAs S. ACss s.> 5 A A &<, J S..> y y; Í s CM hM MA <' 'S AM t M s A'' Μ; ΓΜ sM s' X Msi AUst X';' .'X CAÓ AM W MM AH MG] AsAA t AA Mt S'Us ACt StM Mt XX sM C sC sAC CM t sG MCss Mac sM sUC AAC I i ssss-as-.s-.sssss-.s-.ss-.sss ^S'.S'.'.'.SSSSSXSSSSSX'.S*.XSX'.SX*.'.'.SSSSSSS*.*.SXSSSSSXSSSSXSSSSXSXSX'.*.*.*.SX·.'.·.'.'. .'.SSSSXSSXSX'.SSSXSSSSSSSSSXSXSSSSSSSSSXSXSS-.SX'.SSSSXSSSSSSXV.'.'.'.'.XSSSS*^ S'.SSSSSSSSXSSSXSSSSSSSS ÍMsbM SFssv AM Asss Ms M Ms t ys My M Ms- Ms Ms Xss Ass Ms s ys Ms j ÍMs t ys UN Ms SV$ CX Ab FM Μ M Fs ss Μ X Assy X Ms A Us UM Ayp s yss <M W M Ms VX UX Ms My Usy My Fsn sM Ab My; ΐθο χίο G^ Go >όο €*o GG Go te GG* Gos· >Go GGCGO GX<$ GO Co^ Cyt ÍG Cao Co oo io Gio Lou Go ?o Lvo Í. Asss 28 / 40 29 / 40
[119] Exemplo 2: expressão do peptídeo de fusão do análogo de insulina recombinante
[120] The expression of recombinant insulin analogs was carried out under the control of the T7 promoter. E. coli BL21-DE3 (E. coli B F-dcm ompT hsdS(rB-mB) gal ÀDE3); Novagen) was transformed with each of the recombinant insulin analog expression vectors. The transformation was carried out according to the recommended protocol (Novagen). Individual colonies transformed with each expression vector were collected and inoculated into 2X Luria broth (LB) containing ampicillin (50 pg / mL) and allowed to grow in culture at 37QC for 15 hours. Recombinant strain culture broth and 2X LB medium containing 30% glycerol were mixed in a 1:1 (v / v) ratio. One mL of each was dispensed into a cryotube and stored at 140QC, which was used as a cell reserve for the production of recombinant fusion protein.
[121] For the expression of recombinant insulin analogs, 1 vial from each cell pool was thawed and inoculated into 500 mL of 2X Luria broth and grown in culture, with agitation, at 37°C for 14 to 16 hours. The culture was terminated when the OD600 analysis reached a value of 5.0 or higher. The culture broth was used as seed culture broth. This seed culture broth was inoculated into a 50 L fermenter (MSJ-U2, BEMARUBISHI, Japan) containing 15 L of fermentation medium and an initial fermentation bath was started. The culture conditions were maintained at a temperature of 37°C, air flow rate of 20 L / minute (1 vvm), agitation speed of 500 rpm and pH of 6.70, using 30% ammonia solution. Fermentation was carried out using batch feeding mode by adding a feeding solution once the nutrients in the culture broth were depleted. Strain growth was monitored by the dissolved oxygen (DO) value.IPTG was introduced at a final concentration of 500 μM when the dissolved oxygen (DO) value was greater than 100. After introduction, it was kept under culture for approximately 23 to 25 hours. After completing the culture... 30 / 40 recombinant strains were harvested by centrifugation and stored at -80°C until use.
[122] Example 3: recovery and re-winding of recombinant insulin analog
[123] To modify the recombinant insulin analogs expressed in Example 2 into soluble forms, the cells were disrupted and then re-rolled. 100 g (net weight) of cell clusters were resuspended in 1 L of lysis buffer (50 mM Tris-HCl (pH 9.0), 1 mM EDTA (pH 8.0), 0.2 M NaCl and 0.5% Triton X-100). The cells were disrupted using an M-110EH microfluidizing processor (AC Technology Corp. Model M1475C) at an operating pressure of 15000 psi. The disrupted cell lysate was centrifuged at 7000 rpm and 4QC for 20 minutes. The supernatant was discarded and the cluster was resuspended in 3 L of washing buffer (0.5% Triton X-100 and 50 mM Tris-HCl (pH 8.0), 0.2 M NaCl, 1 mM EDTA). After centrifugation at 7000 rpm and 4QC for 20 minutes, the cell cluster was resuspended in distilled water followed by centrifugation in the same manner.The resulting agglomerate was resuspended in 400 mL of buffer (1 M glycine, 3.78 g cysteine HCl, pH 10m6) and stirred at room temperature for 1 hour. To recover the insulin analog thus resuspended, 400 mL of 8 M urea was added and stirred at 4°C for 1 hour. For rewinding the solubilized recombinant insulin analogs, centrifugation was performed at 7000 rpm and 4°C for 30 minutes, and the supernatant was obtained. 2 L of distilled water were added using a peristaltic pump at a flow rate of 1000 mL / hour, stirring at 4°C, for 16 hours.
[124] Example 4: purification by cation-binding chromatography
[125] The re-rolled sample was loaded onto a Source S column (GE healthcare) in equilibrium with 20 mM sodium citrate buffer (pH 2.0) containing 45% ethanol and eluted from the analog proteins. 31 / 40 insulin in 10 volumes of a linear gradient column from 0% to 100% in 20 mM sodium citrate buffer (pH 2.0) containing 0.5 M potassium chloride and 45% ethanol.
[126] Example 5: treatment with trypsin and carboxypeptidase B
[127] The salts were removed from the eluted samples using a desalting column and the buffer was changed with a buffer (Tris-HCl 10 mM, pH 8.0). With respect to the protein sample obtained, trypsin corresponding to a molar ratio of 1000 and carboxypeptidase B corresponding to a molar ratio of 2000 were added and then stirred at 16QC for 16 hours. To finish the reaction, 1 M sodium citrate (pH 2.0) was used to reduce the pH to 3.5.
[128] Example 6: purification by cation-binding chromatography
[129] The reacted sample was loaded onto a Source S column (GE healthcare) in equilibrium with 20 mM sodium citrate buffer (pH 2.0) containing 45% ethanol and then eluted the insulin analogue proteins in 10 column volumes with a linear gradient from 0% to 100% of 20 mM sodium citrate buffer (pH 2.0) containing 0.5 M potassium chloride and 45% ethanol.
[130] Example 7: purification by anion-binding chromatography
[131] The salts were removed from the eluted sample using a desalting column and the buffer was exchanged with a buffer (Tris-HCl 10 mM, pH 7.5). To isolate a pure insulin analog from the sample obtained in example 6, the sample was loaded onto an anion exchange column (Source Q: GE healthcare) in equilibrium with 10 mM Tris buffer (pH 7.5) and the insulin analog protein was eluted in 10 column volumes with a linear gradient from 0% to 100% of 10 mM Tris buffer (pH 7.5) containing 0.5 M sodium chloride.
[132] The purity of the insulin analogue thus purified was analyzed by protein electrophoresis (SDS-PAGE, FIG. 1) and by high-performance liquid chromatography (HPLC) (FIG. 2) and the amino acid modifications were identified by 32 / 40 peptide mapping (FIG. 3) and molecular weight analysis of each peak.
[133] As a result, it was concluded that each insulin analogue had the desired modification in its amino acid sequence.
[134] Example 8: preparation of the insulin analogue conjugate (N2. 7) Immunoglobulin Fc
[135] To perform pegylation of the N-terminal beta chain of the insulin analog using 3,4K ALD2 PEG (NOF, Japan), the insulin analog and PEG were reacted in a molar ratio of 1:4, with an insulin analog concentration of 5 mg / mL, at 4QC for approximately 2 hours. At this point, the reaction was carried out in 50 mM sodium citrate at pH 6.0 and 45% isopropanol. 3.0 mM sodium cyanoborohydride was added as a reducing agent and the reaction was allowed to proceed. The reaction solution was purified using an SP-HP column (GE Healthcare, USA) with a buffer containing sodium citrate (pH 3.0) and 45% ethanol, and a KCl concentration gradient.
[136] To prepare an insulin analog-immunoglobulin Fc fragment conjugate, purified mono-PEGylated insulin analog and immunoglobulin Fc fragment were reacted in a molar ratio between 1:1 and 1:2 at 25QC for 13 hours, with a total protein concentration of approximately 20 mg / mL. At this point, the reaction buffer conditions were 100 mM HEPES at pH 8.2, and 20 mM sodium cyanoborohydride was added as a reducing agent. Thus, PEG bound to the N-terminus of the Fc fragment.
[137] After the reaction was complete, the reaction solution was loaded onto a Q HP column (GE Healthcare, USA) with Tris-HCl buffer (pH 7.5) and a NaCl concentration gradient to separate and purify the unreacted Fc fragment and mono-PEGylated insulin analog.
[138] Next, a Source 15ISO (GE Healthcare, USA) was used as a secondary column to remove the remaining Fc immunoglobulin fragment and the conjugate, in which two or more insulin analogs were bound to the Fc immunoglobulin fragment, thus obtaining the insulin analog-Fc immunoglobulin fragment conjugate. At this point, elution was performed. Using an ammonium sulfate concentration gradient containing TrisHCl (pH 7.5), the insulin analog-immunoglobulin Fc fragment conjugate eluted in this way was analyzed by protein electrophoresis (SDS-PAGE, FIG. 4) and high-performance liquid chromatography (HPLC) (FIG. 5). The results showed a purity of almost 99%.
[139] Example 9: comparison of insulin receptor binding affinity between native insulin, insulin analog, native insulin-Fc immunoglobulin conjugate and insulin analog-Fc immunoglobulin conjugate
[140] To measure the insulin receptor binding affinity of the insulin-Fc immunoglobulin analog conjugate, surface plasmon resonance (SPR, BIACORE 3000, GE healthcare) was used for analysis. Insulin receptors were immobilized on a CM5 chip by amine coupling, and 5 or more dilutions of native insulin, insulin analog, native insulin-Fc immunoglobulin conjugate, and insulin-Fc immunoglobulin analog conjugate were applied to it independently. Then, the insulin receptor binding affinity of each substance was examined. The binding affinity of each substance was calculated using the BIAevaluation software application. At this point, the Langmuir 1:1 binding model with baseline shift was used.
[141] As a result, compared with human insulin, the insulin analog (nQ. 6) showed a receptor binding affinity of 14.8%, the insulin analog (nQ. 7) showed a receptor binding affinity of 9.9%, the insulin analog (nQ. 9) showed a receptor binding affinity of 57.1%, the insulin analog (nQ. 9) showed a receptor binding affinity of 78.8%, the native insulin-Fc immunoglobulin conjugate showed a receptor binding affinity of 3.7%-5.9% depending on the experimental cycles, the insulin analog (no. 6)-Fc immunoglobulin conjugate showed a receptor binding affinity of 0.9% or less, the insulin analog (no. 7)-Fc immunoglobulin conjugate 34 / 40 showed a receptor binding affinity of 1.9%, the insulin analog (no. 8)-Fc immunoglobulin conjugate showed a receptor binding affinity of 1.8%, and the insulin analog (no. 9)-Fc immunoglobulin conjugate showed a receptor binding affinity of 3.3% (Table 4). Thus, it was observed that the insulin analogs of the present invention showed a reduced receptor binding affinity compared to native insulin, and the insulin analog-Fc immunoglobulin conjugates also showed a notably reduced insulin receptor binding affinity. 35 / 40 Ctompewis da de a® de Imulina Test» n® Mom ds ssbst&nsls IW ^(Vs,xirs) íMW) ; Tests 1 Images hsmam cedes '$ ··> A<tw^> Λ ·^ will draw aa currency A.nWgs of iosd^?a (a^) w W-SW to e a. ao Wd aow : Tests 2 hwHm hemes esWs Λ <'& Z ·· <· Λ» a ' oow w OWÒ Cee^gads ds inauiOa cades - Fc ds imune^ahslma SW / aa < ··'··. .- X >; : : your; ? Áj. / Xí C&wgade do scdtoge de images (nto) - % of w wkwa ãcà ;.s ve / as owo aao aas Tests 3 native hsmsm L'C ws ÓOW wo sKAes Anas^o de mWna (egade) SM aw W. sa (0; Wics a) Fc of Wec^ / wOa να or s.íH oaw ; £$ 5 73⁄4 í ww / 10%) Tests 4 imsgea bus» cades AMIogo of images (n^j ta of oa oo λ a $ oww w oag? ao {ά ά ) Conjugated to this one aadv». > Fc of imvnogtebegns ca aw 03 W. : A s Π<8 o·, w Blindness of insulin anabs (cto) * Fc of imvnogbMds d / 3 aw : U $ ίΜδ%} a ? s' áoà Taste 5 images hamsaa falls 3.0 Oda? ΰ.7 w OdW Aedlege de W» (n^} ta ta so) as swaã ao Coligado da msaims aatve«Fc de imo^lebegca oa aao w ww asm όαα Cea^ade do anddsgo de feseSm (nto) - Fc de imto^bbu§ns Odd O;W o : < asa asem (OSí. 36 / 40
[143] Example 10: comparison of in-vitro efficacy between native insulin-Fc immunoglobulin conjugate and insulin-Fc immunoglobulin analog conjugate
[144] To evaluate the in vitro efficacy of the immunoglobulin Fc insulin analog conjugate, differentiated 3T3-L1 adipocytes from mice were used to test glucose uptake or lipid synthesis. 3T3-L1 cells were subcultured in 10% NBCS (newborn calf serum) containing DMEM (Eagle's medium modified by Dulbeco, Gibco, nQ. de Cat. 12430), two to three times a week, and maintained. 3T3-L1 cells were suspended in a differentiation medium (10% FBS containing DMEM) and then inoculated at a density of 5 x 104 per well in a 48-well plate and grown in culture for 48 hours. For adipocyte differentiation, 1 pg / mL of human insulin (Sigma, nQ- cat. I9278), 0.5 mM IMBX (3-isobutyl-1-methylxanthine, Sigma, nQ. cat. I5879) and 1 μM dexamethasone (Sigma, nQ. cat. D4902) were mixed with the differentiation medium, and 250 μL of the mixture were added to each well after removing the previous medium.After 48 hours, the medium was changed to differentiation medium supplemented with only 1 pg / mL of human insulin. Then, while changing the medium to differentiation medium supplemented with 1 pg / mL of human insulin every 48 hours, the induction of adipocyte differentiation was examined for 7 to 9 days. To test glucose uptake, differentiated cells were washed once with serum-free DMEM medium and then 250 pL was added to induce serum depletion for 4 hours. Serum-free DMEM was used to perform serial 10x dilutions for human insulin from 2 pM to 0.01 pM, and for native insulin-Fc immunoglobulin conjugate and insulin-Fc immunoglobulin analog conjugates from 20 pM to 0.02 pM. Each 250 pL of the prepared sample was added to the cells and cultured in an incubator with 5% CO2 at 37°C for 24 hours.To measure the residual amount of glucose in the medium after incubation, 200 µL of medium was taken and diluted 5 times with D-PBS, followed by... 37 / 40 if a GOPOD assay (GOPOD assay kit, Megazyme, nQ. cat. K-GLUC). Based on the absorbance of the standard glucose solution, the remaining glucose concentration in the medium was converted and the EC50 values for glucose uptake of the native insulin-Fc immunoglobulin conjugate and the insulin-Fc immunoglobulin analog conjugates were calculated, respectively.
[145] As a result, compared with human insulin, the native insulin-Fc immunoglobulin conjugate showed a glucose uptake of 11.6%, the insulin analog (nQ. 6)-Fc immunoglobulin conjugate showed a glucose uptake of 0.43%, the insulin analog (nQ. 7)-Fc immunoglobulin conjugate showed a glucose uptake of 1.84%, the insulin analog (nQ. 8)-Fc immunoglobulin conjugate showed a glucose uptake of 16.0%, and the insulin analog (nQ. 9)-Fc immunoglobulin conjugate showed a glucose uptake of 15.1% (Table 5). Thus, it was observed that the insulin analog (nQ. 6)-Fc immunoglobulin conjugate and the insulin analog (nQ. 7)-Fc immunoglobulin conjugate of the present invention exhibited a notably reduced titer in vitro, compared to the native insulin-Fc immunoglobulin conjugate, and the insulin analog (nQ. 7)-Fc immunoglobulin conjugate.8)-Immunoglobulin Fc and the insulin analog conjugate (nQ. 9)-Immunoglobulin Fc showed an in vitro titer similar to that of the native insulin-Immunoglobulin Fc conjugate.
[146] [Table 5] 38 / 40 Test n® Substance Name Glucose Absorption (relative to native insulin) Test 1 Native human insulin Native insulin conjugate - Immunoglobulin 116% Insulin analog conjugate n® * Immunoglobulin conjugate 0.43% Insulin analog conjugate n® - Immunoglobulin conjugate 1.64% Test 2 Native human insulin Native insulin conjugate - Immunoglobulin conjugate 15.2% Insulin analog conjugate - Immunoglobulin conjugate 16.0% Test 3 Native human insulin Native insulin Immunoglobulin conjugate n® - Immunoglobulin conjugate n® - Immunoglobulin conjugate
[147] Example 11: Pharmacokinetics of the insulin-Fc immunoglobulin analogue conjugate
[148] To examine the pharmacokinetics of the insulin-Fc immunoglobulin analog conjugates, their blood concentration was compared over time in normal rats (SD rats, males, 6 weeks old), adapted to the laboratory for 5 days. Subcutaneous injections of 21.7 nmol / kg of native insulin-Fc immunoglobulin conjugate and 65.1 nmol / kg of native insulin-Fc immunoglobulin conjugate were administered. Blood was collected at 0, 1, 4, 8, 24, 48, 72, 96, 120, 144, 168, 192, and 216 hours. At each collection time, blood concentrations of native insulin-Fc immunoglobulin conjugate and insulin-Fc immunoglobulin analog conjugate were measured by enzyme-linked immunosorbent assay (ELISA) using ELISA. 39 / 40 insulin (ALPCO, USA) was used as the kit. However, a mouse anti-human IgG4 antibody conjugate with HRP (Alpha Diagnostic Inti, Inc, USA) was used as the detection antibody.
[149] The pharmacokinetic results examined of the native insulin-Fc immunoglobulin conjugate and the insulin-Fc immunoglobulin analogue conjugate showed that their blood concentrations in proportion to the two administration concentrations and that the insulin-Fc immunoglobulin analogue conjugates, having a reduced insulin receptor binding affinity, exhibited a considerably increased half-life period, compared to the native insulin-Fc immunoglobulin conjugate (FIG. 6).
[150] These results suggest that when the insulin analogs of the present invention, modified to have a reduced insulin receptor binding affinity, are linked to the Fc region of immunoglobulin for the preparation of conjugates, the conjugates can be provided as stable insulin formulations due to a notably increased in vivo half-life, and thus can be effectively used as therapeutic agents for diabetes. Furthermore, since the insulin analogs according to the present invention also exhibit a reduced insulin receptor binding affinity and a reduced titer, the insulin analogs can also exhibit the same effect even when linked to various other vehicles.
[151] Based on the preceding description, it will be evident to those skilled in the art that it is possible to make various modifications and alterations without departing from the scope and spirit of the invention. Therefore, it should be noted that the previous variant is not limiting, but merely illustrative in all respects. The scope of the invention is defined by the appended claims and not by the description preceding them, and therefore all alterations and modifications that are covered by the goals and limits of the claims, or equivalents of such goals and limits, are intended to be covered by 40 / 40 claims.
Claims
1. Insulin analog showing reduced insulin titer compared to the native form, characterized by having one amino acid modified in the B chain or A chain of insulin.
2. Insulin analogue according to claim 1, characterized in that the reduced insulin titer is attributed to a reduced affinity for binding to the insulin receptor.
3. Insulin analogue according to claim 1, characterized in that the amino acid is modified by replacing an amino acid selected from the set consisting of amino acids 8Q, 23Q, 24Q and 25Q of chain B and amino acids 1Q, 2Q and 19Q of chain A with alanine or is modified by replacing amino acid 14Q of chain A with glutamic acid or asparagine.
4. Insulin analog according to claim 1, characterized in that the insulin analog is selected from the set consisting of SEQ ID Nos. 20, 22, 24, 26, 28, 30, 32, 34 and 36.
5. Insulin analog conjugate, characterized by being prepared by linking (i) the insulin analog as defined in any one of claims 1 to 4; and (ii) a biocompatible material selected from the set consisting of polyethylene glycol, fatty acid, cholesterol, albumin and its fragments, albumin-binding materials, polymers of repeating units of a particular amino acid sequence, antibodies, antibody fragments, FcRn-binding materials, in vivo connective tissue or its derivatives, nucleotides, fibronectin, transferrin, saccharides and polymers as a vehicle capable of prolonging the in vivo half-life of the insulin analog.
6. Insulin analog conjugate according to claim 5, characterized in that the insulin analog and the biocompatible material are linked together through a peptide or a non-peptide polymer as a linker. 2 / 4 7. Insulin analog conjugate according to claim 5, characterized in that the FcRn binding material is an Fc region of immunoglobulin.
8. Insulin analog conjugate according to claim 6, characterized in that the insulin analog conjugate is prepared by linking (i) the insulin analog as defined in any one of claims 1 to 4 and (ii) an Fc region of immunoglobulin via a (iii) peptide linker or a non-peptide linker selected from the set consisting of polyethylene glycol, polypropylene glycol, ethylene glycol-propylene glycol copolymers, polyoxyethylated polyols, polyvinyl alcohol, polysaccharides, dextran, polyvinyl ethyl ether, biodegradable polymers, lipid polymers, chitins, hyaluronic acid and combinations thereof.
9. Insulin analog conjugate according to claim 8, characterized in that the non-peptide linker is attached to the N-terminus of the B chain of the insulin analog.
10. Insulin analog conjugate according to claim 8, characterized in that both ends of the non-peptidic polymer are linked to the N-terminus of the Fc region of immunoglobulin and to the amine group of the N-terminus of the insulin analog or to the ε-amino group or to the thiol group of the internal lysine residue of chain B, respectively.
11. Insulin analog conjugate according to claim 8, characterized in that the Fc region of the immunoglobulin is non-glycosylated.
12. Insulin analog conjugate according to claim 8, characterized in that the Fc region of the immunoglobulin consists of 1 domain to 4 domains selected from the set consisting of the CH1, CH2, CH3 and CH4 domains.
13. Insulin analog conjugate according to claim 8, characterized in that the immunoglobulin Fc region is an Fc region derived from IgG, IgA, IgD, IgE or IgM.
14. Insulin analog conjugate according to claim 3 / 4 13, characterized in that each domain of the Fc region of immunoglobulin is a hybrid of domains that have different origins and that were derived from an immunoglobulin selected from the set consisting of IgG, IgA, IgD, IgE and IgM.
15. Insulin analog conjugate according to claim 8, characterized in that the Fc region of the immunoglobulin further includes a hinge region.
16. Insulin analog conjugate according to claim 13, characterized in that the Fc region of the immunoglobulin is a dimer or a multimer consisting of single-chain immunoglobulins consisting of domains of the same origin.
17. Insulin analog conjugate according to claim 13, characterized in that the immunoglobulin Fc region is an IgG4 Fc region.
18. Insulin analog conjugate according to claim 17, characterized in that the immunoglobulin Fc region is an unglycosylated Fc region derived from human IgG4.
19. Insulin analog conjugate according to claim 8, characterized in that the reactive group of the non-peptidic linker is selected from the set consisting of an aldehyde group, a propionaldehyde group, a butyraldehyde group, a maleimide group and a succinimide derivative.
20. Insulin analogue conjugate according to claim 19, characterized in that the succinimide derivative is succinimidyl propionate, carboxymethyl-succinimidyl, hydroxy-succinimidyl or succinimidyl carbonate.
21. Insulin analog conjugate according to claim 8, characterized in that the non-peptidic linker has reactive aldehyde groups at both ends.
22. Long-acting insulin formulation having improved duration and in vivo stability, characterized by comprising the insulin analogue conjugate as defined in claim 6. 4 / 4 23. Long-acting insulin formulation according to claim 22, characterized in that the formulation is a therapeutic agent for diabetes.
24. Method for preparing the insulin analog conjugate as defined in claim 6, characterized by comprising the steps consisting of: i. preparing an insulin analog; ii. preparing a biocompatible material selected from the set consisting of an FcRn binding material, fatty acid, polyethylene glycol, an amino acid fragment and albumin; and iii. linking the insulin analog to the biocompatible material.
